bronchoscopy
(2)
CSA Medical, Inc.
CSA Medical is a Lexington, Massachusetts medical device company that develops spray cryotherapy technology for the lungs. Its flagship RejuvenAir System delivers a metered dose of -196°C liquid nitrogen through a bronchoscope to destroy the damaged, mucus-producing cells that drive chronic bronchitis in COPD patients, while preserving the underlying tissue matrix so healthy airway cells can regrow. Backed by roughly $161M in total funding including a $53M Series D in 2024, the company submitted its FDA PMA in January 2026 following a successful pivotal SPRAY-CB trial.
Apreo Health
Apreo Health is a clinical-stage medical device company in Menlo Park, California developing the BREATHE Airway Scaffold, a bronchoscopically delivered, self-expanding nitinol implant that relieves lung hyperinflation in patients with severe emphysema. Unlike existing valve and surgical treatments that collapse or remove lung tissue, the scaffold gently tents open damaged airways to release trapped air while sparing healthy tissue, aiming to expand who can be treated. The company raised a $130M Series B in August 2025 to run its pivotal BREATHE-3 trial and prepare for early commercialization.